50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to apply the Versamune ® platform, our proprietary and versatile immunotherapy technology, to develop a new generation of immuno-oncology products that are effective and safe across a broad range of cancer types.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2790% match
“Our mission is to develop new and effective immune-oncologic therapeutics.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-10-1472% match
“Our mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through our subsidiary MiNK Therapeutics, Inc. (“MiNK”)), and vaccine adjuvants (through our subsidiary SaponiQx, Inc. (“SaponiQx”)).”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1471% match
“Our mission is to create differentiated, innovative products by applying our platform technologies to established or novel medicines.”In use 2008 – now·1 sighting·SEC Form 10-K, filed 2008-02-2970% match
“Our mission is to overcome the limitations of cytokine therapies and checkpoint inhibitors, such as anti-CTLA-4, and make immunotherapies beyond anti-PD-1/PD-L1 treatments more accessible, efficacious and safe for patients with cancer.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-0169% match
“Our mission is to improve overall patient condition through innovative bio-immunotherapy with proven treatment protocols, to lower deaths associated with cancer and to reduce the cost of cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2569% match
“Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1969% match
“Our mission is to bring off-the-shelf cellular immunotherapies with disease-transforming potential initially to patients with autoimmune diseases and cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2669% match
“Our mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-03-1569% match
“Our mission is to harness the evolutionary power of the human immune system to provide patients fighting cancer with safe, effective therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1869% match
“Our mission is to develop a portfolio of innovative product candidates for the treatment of cancer.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-02-0769% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0569% match
“Our mission is to advance humanity by engineering immunotherapies that are safer, more effective, and broadly accessible.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3168% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2868% match
“Our mission is to alleviate the most human suffering possible by developing active immunotherapy product candidates that improve the quality of care for chronic diseases and are accessible to all patients across the globe.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2768% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1668% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2468% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0468% match
“Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1068% match
“Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1768% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1667% match
“Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3067% match
“Our mission is to develop and apply proprietary technologies that improve the safety and effectiveness of therapeutic and diagnostic healthcare delivery systems.”In use 2010 – now·1 sighting·SEC Form 10-K, filed 2010-02-2567% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0967% match
“Our mission is to develop and commercialize innovative antibody-based therapeutics for the treatment of solid tumors that are designed to bind depending on the physical and chemical properties of tumors and their microenvironment.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-04-2967% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0866% match
“Our mission is to transform patients’ lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology.”In use 2025 – now·1 sighting·SEC Form 20-F, filed 2025-03-2066% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0766% match
“Our mission is to leverage an integrated and extensive genomics and transcriptomics discovery engine to identify antibodies targeted to newly discovered neoepitopes and to mobilize the human immune system of cancer patients to kill tumor cells and facilitate long-term remission.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-1566% match
“Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following:.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2866% match
“Our mission is to enable anyone and any company to use our integrated open-access drug discovery and development platform to discover and develop new therapeutic products to benefit patients worldwide.”In use 2015 – now·1 sighting·SEC Form 20-F, filed 2015-04-1566% match
“Our mission is to become the world leader in the sustainable manufacture of KLH and use our unique, proprietary methods and intellectual property to serve the growing demand for KLH in immunotherapeutic and immunodiagnostic markets.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-12-1466% match
“Our mission is to develop and produce innovative, life-changing technologies to enable patients to become their ‘best possible self’, in the safest and most effective manner.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-02-1066% match
“Our mission is to use our immunotherapies and apply them to veterinary medicine.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-04-1666% match
“Our mission is to improve health with technologies that transform the way that antibody-based therapies are discovered.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-02-2566% match
“Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-0166% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1066% match
“Our mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2166% match
“Our mission is to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-06-2266% match
“Our mission is to improve the lives of patients throughout the world by successfully identifying, developing and commercializing innovative specialty biopharmaceutical products.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-02-2865% match
“Our mission is to benefit patients by developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, with particular focus on orphan cancer indications.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-10-0765% match
“Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2665% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2465% match
“Our mission is to develop next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-11-2865% match
“Our mission is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-1465% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0165% match
“Our mission is to create life-changing T cell therapies for patients with cancer and autoimmune disorders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0465% match
“Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0665% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2865% match
Showing 1–50 of 50